Bladder Cancer in 2010 How Far Have We Come?

被引：290

作者：

Jacobs, Bruce L. ^{[1
]}

Lee, Cheryl T. ^{[2
]}

Montie, James E. ^{[3
]}

机构：

[1] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15213 USA

[2] Director Bladder Canc Program, Dept Urol, Ann Arbor, MI 48109 USA

[3] Taubman Ctr, Dept Urol, Ann Arbor, MI 48109 USA

来源：

CA-A CANCER JOURNAL FOR CLINICIANS | 2010年 / 60卷 / 04期

关键词：

TRANSITIONAL-CELL-CARCINOMA; BACILLUS-CALMETTE-GUERIN; INVASIVE UROTHELIAL CARCINOMA; LYMPH-NODE DISSECTION; COLONY-STIMULATING FACTOR; PHASE-II TRIAL; REPEAT TRANSURETHRAL RESECTION; INDUCED FLUORESCENCE DIAGNOSIS; ASSISTED RADICAL CYSTECTOMY; INTRAVESICAL MITOMYCIN-C;

D O I：

10.3322/caac.20077

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article. CA Cancer J Clin 2010;60:244-272. (C) 2010 American Cancer Society, Inc.

引用

页码：244 / 272

页数：29

共 245 条

[11] Clinical model of lifetime cost of treating bladder cancer and associated complications
Avritscher, Elenir B. C.
Cooksley, Catherine D.
Grossman, H. Barton
Sabichi, Anita L.
Hamblin, Lois
Dinney, Colin P.
Elting, Linda S.
[J]. UROLOGY, 2006, 68 (03) : 549 - 553
[12] EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder
Babjuk, Marko
Oosterlinck, Willem
Sylvester, Richard
Kaasinen, Eero
Boehle, Andreas
Palou-Redorta, Juan
[J]. EUROPEAN UROLOGY, 2008, 54 (02) : 303 - 314
[13] Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group
Bamias, A
Aravantinos, G
Deliveliotis, C
Bafaloukos, D
Kalofonos, C
Xiros, N
Zervas, A
Mitropoulos, D
Samantas, E
Pectasides, D
Papakostas, P
Gika, D
Kourousis, C
Koutras, A
Papadimitriou, C
Bamias, C
Kosmidis, P
Dimopoulos, MA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) : 220 - 228
[14] A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer
Bellmunt, J
de Wit, R
Albanell, J
Baselga, J
[J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (17) : 2212 - 2215
[15] Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium
Bellmunt, J
Guillem, V
Paz-Ares, L
González-Larriba, JL
Carles, J
Batiste-Alentorn, E
Sáenz, A
López-Brea, M
Font, A
Nogué, M
Bastús, R
Climent, MA
de la Cruz, JJ
Albanell, J
Banús, JM
Gallardo, E
Diaz-Rubio, E
Cortés-Funes, H
Baselga, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) : 3247 - 3255
[16] Neoadjuvant chemotherapy for bladder cancer
Black, Peter C.
Brown, Gordon A.
Grossman, H. Barton
Dinney, Colin P.
[J]. WORLD JOURNAL OF UROLOGY, 2006, 24 (05) : 531 - 542
[17] The impact of variant histology on the outcome of bladder cancer treated with curative intent
Blacks, Peter C.
Brown, Gorton A.
Dinney, Colin P. N.
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (01) : 3 - 7
[18] BLOMJOUS CEM, 1989, CANCER, V64, P1347, DOI 10.1002/1097-0142(19890915)64:6<1347::AID-CNCR2820640629>3.0.CO
[19] 2-Q
[20] Böhle A, 2004, UROLOGY, V63, P682, DOI 10.1016/j.urology.2003.11.049

← 1 2 3 4 5 6 7 8 9 10 →